Kornimate/medical-research-clean huggingface dataset:
quality of life and visual function in uveitis patients

Conditions: Anterior Uveitis; Posterior Uveitis; Panuveitis; Uveitis

Summary: the purpose of this study was to measure the quality of visual function and quality of daily living in patients with anterior, posterior, and panuveitis.

the national eye institute visual functioning questionnaire, version august 2000 (nei vfq-25) and the medical outcomes study (mos) 36 item short form health survey instrument (sf-36) (rand 36-item health survey 1.0 questionnaire) will be administered by a trained interviewer. socio-demographic and clinical data will be collected for additional qol parameter.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent * subjects of either gender * age greater than or equal to 18 years of age * diagnosed with uveitis

Keywords: uveitis quality of life visual function
developing oral lt3 therapy for heart failure - hfref

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF); Low T3 Syndrome

Summary: investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with liothyronine (lt3) in individuals with heart failure with reduced ejection fraction (hfref) and low triiodothyronine (t3) syndrome by conducting a randomized, double-blind, placebo-controlled cross-over study with a two-week washout period between treatments.

the overall goal is to determine the safety, feasibility, and preliminary efficacy of administering oral lt3 therapy in the study population of participants with heart failure with reduced ejection fraction (hfref). the study will consist of two treatment periods - each treatment period will be approximately 8 weeks in duration, with weekly titration of study drug for 4 weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to the other arm (placebo or drug). lt3 will be titrated to t3 levels.

Eligibility criteria:
inclusion criteria: 1. men and women aged ≥18 years 2. nyha class i, ii or iii heart failure 3. ef≤40 percent within the past year 4. an implantable cardioverter-defibrillator (icd) 5. stable doses of neurohormonal blockade for 30 days 6. tsh and free t4 level within the laboratory reference range and total t3 level \<94 ng/dl exclusion criteria: 1. hypertrophic or restrictive cardiomyopathy 2. uncorrected severe primary valvular disease 3. arrhythmia that results in irregular heart rate 4. inability to perform vo2max exercise testing 5. severe lung disease, including treatment with oral steroids within past 6 months for exacerbation of obstructive lung disease or use of daytime supplemental oxygen 6. serum creatinine \> 3.0 mg/dl 7. history of cirrhosis 8. lvad use 9. heart failure hospitalization within past month 10. acute coronary syndrome, coronary intervention or ablation therapy within past 2 months or cardiac surgery, percutaneous repair of a valve or septal defect repair within the past 6 months 11. taking thyroid extract, lt4, lt3, amiodarone, or medication that affects the absorption or metabolism of thyroid hormone; gastrointestinal conditions that affect the absorption of thyroid hormone 12. if female, current or planned pregnancy within the timeframe of study participation 13. any medical condition that in the opinion of the investigator, will interfere with the safe completion of the study.

Keywords: heart failure hfref low t3 syndrome
diagnostic role of antiphospholipid antibodies and microparticles in immune thrombocytopenic patients with thrombosis

Conditions: Thrombosis

Summary: identify the procoagulant profile in immune thrombocytopenic patients with thrombosis. clinical implications of antiphospholipid antibodies in itp patients with thrombosis. diagnostic role of microparticles in itp patients with thrombosis.

immune thrombocytopenia (itp) is an acquired autoimmune disorder characterized by isolated thrombocytopenia and an increased risk of bleeding. paradoxically, itp is also associated with an increased risk of thrombosis (1). recent studies showed that the occurrence of thrombosis in patients with itp is not purely accidental and can be considered a clinical reality with an important impact on the management of the disease (2). the pathophysiological mechanism for thrombosis in itp remains unclear. sever bleeding episodes are relatively rare in some patients with itp although having low platelet count, suggests that these patients may have a protective factor against bleeding (3). antiphospholipid (apl) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (la), β2glycoprotien і (β2gpі), and anticardiolipin (anti-cl). they interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells (4). microparticles (mps) are a diverse group of bioactive small-sized vesicles (100-1000nm) that can be found in body fluids and blood after activation, necrosis, or apoptosis of almost all cells. although most mps in human blood originate from platelets, mps are also released from leukocytes, erythrocytes, endothelial cells, smooth muscle cells and cancer cells (5). they participate in intercellular communication and play a major role in homeostasis under physiological conditions and also in diseases (6). the most prominent property of mps is their procoagulant potential, mainly based on phosphatidylserine exposure and tissue factor expression (7). elevated levels of antiphospholipid antibodies and microparticles have been reported as a risk for development of prothrombotic state (8).

Eligibility criteria:
patients with confirmed diagnosis of primary chronic itp with and without thrombosis, male or female above age of 18.inclusion criteria: exclusion criteria: thrombocytopenic patients due to secondary causes such as pregnant women, patients with uncontrolled hypertension, peripheral or coronary artery disease, abnormal hepatic or renal function tests, bleeding disorder, and thrombopathy well be excluded from the study. patients full fill the criteria of antiphospholipid syndrome (aps).
physical function and mental health in cancer survivors

Conditions: Cancer; Sedentary Behavior; Depressive Symptoms; Survivorship

Summary: the goal of this observational study is to evaluate the joint prognostic effects of physical function and mental health on survival of cancer survivors.

cancer survivors were selected from the national health and nutrition examination survey (nhanes) between 2007 and 2018. total sedentary time was assessed by self-reported daily hours of sitting and depressive symptoms were assessed by patient health questionnaire 9 (phq-9). kaplan-meier (km) curves and the cox regression analyses were used to evaluate the separate and joint prognostic effects of sedentary behavior and depressive symptoms with mortality outcomes of cancer survivors.

Eligibility criteria:
inclusion criteria: * adults with aged above 18 year old exclusion criteria: * without a history of cancers * without records of sedentary behavior or depressive symptoms test * incomplete follow-up information
effect of nebulized lidocaine on postoperative sore throat

Conditions: Sore Throat

Summary: the purpose of this study is to test the hypothesis that use of preoperative nebulized lidocaine is reduced the incidence of postoperative sore throat after endotracheal intubation.

adult patients undergoing video-assisted thoracic surgery (vats) requiring double lumen tube (dlt) endotracheal intubation for one-lung ventilation (olv) were enrolled in the study. patients were randomized by means of computer-generated order randomization into two groups: group c (those who received a saline solution as placebo delivered by nebulization) and group l (those who received lidocaine delivered by nebulization). at 1, 6 and 24 h after tracheal extubation, an observer blinded to treatments evaluated the patients in terms of sore throat and hoarseness. in addition, patients' satisfaction, intraoperative and postoperative opioid and analgesics consumption and complaints such as dysphagia, nausea and vomiting were recorded. hemodynamic variables such as blood pressure and heart rate were also recorded.

Eligibility criteria:
inclusion criteria: * patients undergoing video-assisted thoracic surgery requiring double lumen tube endotracheal intubation for one-lung ventilation * american society of anesthesiologists class 1,2 and 3 * ability to consent exclusion criteria: * patients \<18 years old * body mass index (bmi) \ 35 kg/m2 * mallampati grade 3 or 4 * mouth opening \< 3 cm * preexisting hoarseness or sore throat * coagulopathy * patient with upper respiratory tract infection
levator muscle strength evaluation

Conditions: Ptosis

Summary: the purpose of this study is to assess a new technique of measurement for the levator muscle. this measurement may be applied during a clinical evaluation of eyelid malposition. our purpose is to quantify the levator muscle strength and to corelate it to standard levator muscle strength assessment techniques routinley used in the oculoplastic clinic.

this study will include patients refered to our oculoplastic department for evaluation of eyelid disorders (ptosis or eyelid malpositions due to various mechanical, muscular, neurogenic factors). all patients will be over 21 years old, with eligibility for signing an informed concent form. all patients will undergo a full clinical standard evaluation of eyelid malposition made as part of the routine evaluation of eyelid malpositions. as part of this evaluation- the levator muscles strength will be measured by monitoring the amount of millimeters of difference between the uper lid closed and open position (a regular technique for levator muscles assessment). a second levator muscle strength evaluation will include the study device. this device is used for weight evaluation of objects. an object is measured by attaching it to the device with a metal hook and a string. the device is hand held. for measurements of the upper lid force the device will be temporarily attached to the upper eyelid using a specially designed base made in the shape of the eyelid. the attachment will be using a sterile medical tape (plaster). this sterile base is attached to the outer eyelid and does not involve in any point any harm to the continuity of the skin, injections , harm or contact to the eyeball or any other parts of the eye. this base is attached from its back to a string witch attaches to the measuring device. the investigator holds the measuring device and asks the patient to open and close his eyes. the force that is generated while opening the upper lid is measured (in grams) by the device. this evaluation will allow a unique first proper estimation of the true levator palpebra strength. it will be compared to the levators' strength as estimated using the routine techniques for assessing their efficacy. the assessment will be made one time for each patient. after the measurement- the sterile tape will be removed and will be disposed. no further interventions will be made for each patient.

Eligibility criteria:
inclusion criteria: eligible for signing an informed concent form refered for eyelid evaluation in the oculoplastic department, meir mc exclusion criteria: previous eyelid surgery

Keywords: ptosis blepharochalasis dermatochalasis
emergency contraception - user's profile

Conditions: Postcoital Contraception

Summary: retrospective analysis of requests of emergency hormonal contraception using pharmacy protocols registered in 2003 and 2006.

in 2002, levonorgestrel was introduced in switzerland for emergency hormonal contraception (ec) without prescription ('pharmacist only'). in 2003, a first analysis of requests of ec showed that the dispensing of ec through pharmacies could successfully be implemented (lemke et al 2004). this study was repeated three years later with the aim to explore whether the user's profile has changed after introduction of a low threshold access to ec.

Eligibility criteria:
inclusion criteria: * women seaking emergency hormonal contraception exclusion criteria: -

Keywords: emergency contraception emergency hormonal contraception community pharmacies pharmaceutical care time to access written assessments switzerland
expanded access program of amn107 in imatinib-resistant or intolerant adult patients with chronic myeloid leukemia

Conditions: Chronic Myeloid Leukemia

Summary: this study will further evaluate if amn107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.


Eligibility criteria:
inclusion criteria: * imatinib-resistant or -intolerant philadelphia chromosome-positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase. * chronic myeloid leukemia patients who have been treated with an investigational tyrosine kinase inhibitor. * laboratory values within normal limits. exclusion criteria: * impaired cardiac function. * acute or chronic liver or renal disease considered unrelated to tumor. * other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol. * patients who are currently receiving treatment with any of the medications that have the potential to prolong the qt interval or to inhibit the metabolism of amn107 (cyp3a4/5 inhibitors). * patients with a history of another malignancy that is currently clinically significant or currently requires active intervention. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic myeloid leukemia amn 107 imatinib resistant or intolerant nilotinib enact
hindfoot fusion using intramedullary nail in diabetic ankle arthropathy

Conditions: Charcot Arthropathy of Hindfoot

Summary: the aim of this study is to evaluate the outcome of healing rate of ankle fusion using modified retrograde im femoral nail with plate in charcot ankle

charcot neuroarthropathy, is a progressive, noninfectious, and destructive joint disorder following trauma to a neuropathic extremity.the disorder mainly occurs in the foot and ankle joints. the process consists of bone and joint destruction, joint deformity, ulceration, and, if left untreated, may lead to amputation. the majority of the charcot joint cases are associated with a neuropathic complication in patients with diabetes. thus, with the increase in the current incidence of diabetes, the increase of charcot joint cases is also expected. the treatment of charcot joint is variable including non operative, such as total contact casting, modified shoe, medication, and operative treatment. however, when the deformity is severe and unstable, the operative management is necessary. there are some surgical approaches to manage charcot joint, such as exostectomy, achilles tendon lengthening, arthrodesis with internal or external fixation, and amputation. arthrodesis is indicated in severe charcot joint with significant instability. for charcot ankle arthrodesis, internal fixation is more popular than external fixation in the absence of infection, significant bone defect, and poor soft tissue coverage. some of the methods of internal fixation for ankle arthrodesis include the use of retrograde intramedullary nails, screws, and plates. many surgeons chose retrograde intramedullary nail fixation as the main method of internal fixation. however, limited compression and high nonunion rates have been found with intramedullary nail fixation.so using plate with intramedullary nail will offer stiff constructs, more stability and better union rates. however, studies evaluating the use of combination fixation in the ankle arthrodesis for charcot ankle, particularly nail with plate, are limited. \[13\] so, in this study the investigators will evaluate the outcomes of ankle arthrodesis using a combination of an intramedullary nail with plate in patients with diabetic charcot ankle.

Eligibility criteria:
inclusion criteria: * adult diabetic patients who have (brodsky type 2 and type 3a) charcot ankle and hba1c below 8 exclusion criteria: * prescence of active infection * prescence of ulcers * significant bone defect * vascular insufficiency
effects of bidomain cognitive and aerobic training on cognitive functioning in mild cognitive impairment.

Conditions: Mild Cognitive Impairment

Summary: the study aims to assess the effects of bidomain cognitive and aerobic training on both cognitive functioning and quality of life in individuals with mild cognitive impairment.

the proposed study addresses a notable gap in the literature regarding the comparison between combined cognitive-aerobic training and cognitive training alone in improving cognitive function for patients with mild cognitive impairment (mci). while previous studies have demonstrated the positive effects of both training methods on cognitive function independently, there is currently no research directly comparing their effectiveness when used together. the study aims to provide evidence on which treatment regime-combined cognitive-aerobic training or cognitive training alone-offers better outcomes for mci patients. aerobic training is known to enhance brain structure and function by strengthening neuronal connections, largely due to increased levels of brain-derived neurotrophic factor (bdnf) and enhanced vascularization, which stimulates hippocampal growth. on the other hand, cognitive training improves global cerebral functional connectivity, particularly activating the prefrontal cortex, which leads to better cognitive performance. combining these training modalities may yield greater benefits than focusing on just one, offering a cost-effective, accessible approach that could significantly improve the quality of life and daily functioning for individuals with mci.

Eligibility criteria:
inclusion criteria: * older adults 60 years \& above * with normal vision and color perception * independent individual capable of carrying out daily tasks * individuals scoring 21-25 on the mini-mental state examination (mmse) exclusion criteria: * medication affecting the exercise capacity of individual * regular participation in aerobic training for the last six months * cardiovascular or other diseases that do not allow physical activity * a diagnosed severe psychiatric disease (e.g., depression) * patients with cognitive impairment or other neurological impairments due to ad or dementia.

Keywords: cognition old age mild cognitive impairment aerobic cognitive training
a study comparing ain457 to placebo in subjects with a diagnosis of moderate to severe stable plaque psoriasis

Conditions: Plaque Psoriasis

Summary: this is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of ain457 to placebo. subjects with a diagnosis of moderate to severe stable plaque psoriasis will be randomized to receive either ain457 or placebo. ain457 or placebo will be administered by single infusion at baseline and subjects will be observed for up to 26 weeks following the infusion.


Eligibility criteria:
inclusion criteria: * males or females, aged 18-69 at time of consent. * post menopausal or surgically sterile female patients are allowed. male patients must be willing to use contraception method at least for 3 months following the completion of the study. women of child-bearing potential will not be allowed to participate. * diagnosis of plaque psoriasis for at least 6 months prior to screening. the patients must meet both of the following criterion: 1. coverage of the body surface area (bsa) of 10% or more with plaques 2. a score of 3 or more on the iga scale * stable plaque psoriasis at screening and randomization. * pasi score of 12 or greater at randomization. * able to communicate well with the investigator, and to understand and comply with the requirements of the study. understand and sign the written informed consent. * patients must have normal laboratory values for screening laboratory test results of hematological (hemoglobin, wbcs, neutrophils, platelets) and renal (serum creatinine) assessments. for the transaminases, aspartate aminotransferase and alanine aminotransferase, levels 1.5 times the upper limit of normal will be accepted. for the additional hepatic laboratory results (alkaline phosphatase, gamma-glutamyltransferase, bilirubin), patients must have non-clinically significant values. exclusion criteria: * currently have any of the nonplaque forms of psoriasis: erythrodermic, guttate, or pustular. * currently have drug-induced psoriasis (new onset or exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium). * men who are planning to initiate a pregnancy while enrolled in the study or for 3 months following completion of the study. * women of child-bearing potential are not allowed in the study. * used any investigational drug within the previous 4 weeks. * recent previous treatment with anti-tnf-α therapy (or other biological therapy), immunosuppressive agents such as cyclosporine, mycophenolate, pimecrolimus, or tacrolimus. the following washout period will be required for such patients to be eligible to participate in the trial. 1. 2 months washout prior to screening for etanercept, adalimumab, or infliximab. 2. 1 month washout prior to screening for cyclosporine, mycophenolate, tacrolimus, and any systemic immunosuppressants including, but not limited to, methotrexate, azathioprine, 6-thioguanine, mercaptopurine, and hydroxyurea other protocol-defined inclusion/exclusion criteria may apply

Keywords: plaque psoriasis